Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Dora Ferrari"'
Autor:
Daniel J DeAngelo, Chia-Cheng Li, Amit Verma, Mariano Severgnini, David Nickle, Guillermo Garcia-Manero, Uwe Platzbecker, Reinhard von Roemeling, Klaus H Metzeler, Eric S Winer, Gaurav S Choudhary, Wanying Zhao, Maureen Lane, Alyssa Masciarelli, Dora Ferrari, Cole Gallagher, Samantha Carlisle
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2e667ab0e236414281a1be5dcc4a281e
Autor:
Christina A. von Roemeling, Bently P. Doonan, Rylynn A. Russell, Tyler V. Elliott, Erica Matich, Vincent Archibald, Lan Hoang-Minh, Reinhard W. von Roemeling, Dora Ferrari, Jamison Hoffman, Duane A. Mitchell
Publikováno v:
Cancer Research. 83:LB203-LB203
Introduction: The unique microenvironment within the brain alongside restrictions imparted by the blood brain barrier (BBB) create a sanctuary site for tumors to thrive. Melanoma is often responsive to therapy when present in peripheral tissue, but b
Publikováno v:
Experimental Hematology. 100:S61
Autor:
Lian Hu, Dora Ferrari, Julie C. Sapp, Ashlyn Gruber, Leslie G. Biesecker, Jean Zhao, Brian Schwartz
Publikováno v:
Genetics in medicine : official journal of the American College of Medical Genetics
PurposeProteus syndrome is a rare mosaic overgrowth disorder that is associated with severe complications. While anecdotal data have suggested that the life span of affected patients is reduced, this has not been measured. Mortality data on rare dise
Autor:
Dora Ferrari, Lee S. Rosen, Richard G. Just, Jonathan W. Goldman, Edward Graeme Garmey, Feng Chai, Ronald E. Savage, Isett Laux
Publikováno v:
Cancer. 118:5903-5911
BACKGROUND: Amplification of the mesenchymal-epithelial transition factor (MET) gene can promote tumor resistance to epidermal growth factor receptor (EGFR) inhibition. Dual EGFR-MET inhibition may overcome this resistance. Tivantinib (ARQ 197) is a
Autor:
Dora Ferrari, Yi Yu, Ronald E. Savage, Marjorie J. Lindhurst, Miranda R. Yourick, Leslie G. Biesecker
Publikováno v:
Scientific Reports
A somatic activating mutation in AKT1, c.49G>A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome. ARQ 092 is an allosteric pan-AKT inhibitor under devel
Autor:
Wolfram Brugger, David E. Gerber, Dora Ferrari, Susan T Arthur, Joan H. Schiller, Edward Graeme Garmey, Yinpu Chen, Brian Schwartz, Sergey Orlov, Wallace Akerley, Igor Gorbachevsky, Rodryg Ramlau, Lecia V. Sequist, Joachim von Pawel, Daniel B. Costa
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(24)
Purpose c-MET (MET) receptor activation is associated with poor prognosis and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non–small-cell lung cancer (NSCLC). This global, randomized phase II trial examined
Autor:
Rodryg Ramlau, Wolfram Brugger, Wallace Akerley, Edward Graeme Garmey, Dora Ferrari, Sergey Orlov, J. von Pawel, Lecia V. Sequist, David E. Gerber, Joan H. Schiller
Publikováno v:
Journal of Clinical Oncology. 28:LBA7502-LBA7502
LBA7502 Background: Orally administered ARQ197 is a selective, non-ATP competitive inhibitor of c-MET (MET), a receptor TK implicated in cancer cell migration, invasion, and proliferation. Dual EGFR-MET inhibition is a promising strategy for overcomi